The effect of an oral lipid load on plasma lipids, apolipoproteins and lipoproteins. by Fung, Siu-fan. & Chinese University of Hong Kong Graduate School. Division of Clinical and Pathological Sciences.
THE EFFECT OF AN ORAL LIPID LOAD 
ON PLASMA LIPIDS, APOLIPOPROTEINS AND LIPOPROTEINS 
Thesis submitted for the 
MSc in Clinical Biochemistry 
Clinical & Pathological Sciences Division 







I am grateful to my supervisor, Dr C. W. K. Lam, 
Senior Lecturer, Department of Chemical Pathology, the 
Chinese University of Hong Kong, for his supervision 
and instruction for this study. I must thank Professor 
J Masarei, Chairman, Department of Chemical Pathology, 
the Chinese University of Hong Kong for proof reading. 
I am also grateful to Dr A. Y. W. Chan, former 
Lecturer, Department of Chemical Pathology, the 
Chinese University of Hong Kong, who recruited 
volunteers and prepared blood samples for this study. 
I must also thank Professor R. Swaminathan, former 
chairman of Department of Chemical Pathology, the 
Chinese University of Hong Kong who instructed me in 
writing my thesis. Mr. C. S. Ho, scientific Officer of 
Chemical Pathology Department, Prince of Wales 
Hospital, also helped me a lot in working with 
computer programs. 
Finally I would like to thank all ,the staff of 
Metabolic Investigation Unit, Prince of Wales Hospital 








List of Tables 9 
List of Figures 12 
Reference Ranges 14 
Abbreviations 15 
1. Introduction 16 
1.1. Clinical biochemistry of lipids, 16 
apolipoproteins and lipoproteins 
1."1.1. Lipids: definition and physiological 16 
importance 
1.1.2. Lipoproteins and apolipoproteins 16 
1.1.3. Lipoprotein metabolism 19 
1.1.3.1. Digestion and absorption of lipids 19 
1.1.3.2. Exogenous lipoprotein metabolism ) 20 
1.1.3.3. Endogenous lipoprotein metabolism 21 
1.1.4. Dyslipoproteinaemia and atherosclerosis 22 
-3-
.~ , 
1.1.4.1. Risk factos associated with 22 
atherosclerosis 
1.1.4.2. Plasma cholesterol, lipoproteins and 23 
atherosclerosis 
1.1.4.3. Plasma triglyceride and atherosclerosis 25 
1.1.4.4. Apolipoprotein A-I (apo A-I), 25 
apolipoprotein B (apo B) and atherosclerosis 
1.1.4.5. Postprandial lipidaemia and 26 
atherosclerosis 
1.2. Lipid metabolism in diabetes mellitus 29 
1.2.1. Diabetes mellitus 29 
1.2.2. Lipoprotein metabolism in non-insulin 30 
dependent diabetes mellitus (NIDDM) 
1.3. Lipid tolerance test 32 
1.3.1. General discussion 32 
1.3.2. Use of Maxolon 33 
1.4. Objectives 34 
2. Materials and methods 36 
2.1 Materials 36 
2.2 Subjects and patients 37 
2.2.1. Healthy subjects 37 
2.2.2. NIDDM patients 37 
2.2.3. Glucose intolerant (IGT) patients 37 
-4-
· ' :, ., ". 
,o ' 
f , _~ 
2.2.4 Study design :38 
2.3. Blood samples 39 
2.3.1. Serum samples 39 
2.3.2. Serum triglyceride-rich lipoproteins 39 
(TRL) fraction 
2.4. Analytical methods 
2.4.1. Cholesterol 
2.4.2. Triglyceride 
2.4.3. HDL-cholesterol · 
2.4.4. Apo A-1 and Apo-B 
2.5. Measurement of postprandial serum 
triglyceride and TRL triglyceride 
















To investigate the effect of Maxolon on the 
duration of a lipid loadin'g , test using Intralipidl , 13 
normal subjects were studied. Every normal subject was 
studied twice, each consumed an amount of fat 
emulsion, 10' IntralipidR containing 0.5 9 fat/kg body 
weight, with and without intravenous Maxolon injection 
(2 mL containing 10 mg). Blood was collected before 
and hourly after the ingestion of IntralipidR for 5 
hours (with Maxolon injection) and 6 hours (without 
Maxolon injection). Concentrations of serum 
triglyceride (TG), cholesterol (TC), HDL-cholesterol 
(HDL-C), apolipoproteins A-I and B (apo A-I and Apo B) 
were measured in serum. Triglyceride-rich lipoprotein 
fraction (d < 1.006 g/mL, TRL) was isolated and TG and 
TC were measured. Serum TG concentration rose after 
the oral lipid loading and then returned to the 
fasting level. The mean oftriglyceridaemia peak hour 
(2 hours) with the Maxolon injection occurred 
significantly earlier (p = 0.0006) than that 
(4 hours) without Maxolon injection. Maxolon was 
therefore shown to be ;, able to shorten the duration of 
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the oral lipid loading test. This modified lipid 
loading test was applied to patients with non-insulin 
dependent diabetes mellitus (NIDDM) or glucose 
intolerant (IGT) patients who are known to have 
abnormality in I lipid and lipoprotein metabolism. 
Nineteen NIDDM patients and 14 IGT patients with 
normal or mildly elevated fasting serum TG 
concentration were studied. All patients received oral 
IntralipidR with Maxolon injection and blood was 
collected before and hourly for 5 hours after the oral 
lipid loading. Serum and TRL TG in all subjects rose 
and fasting serum and TRL TG correlated wi th the 
postprandial increases (measured as the area under the 
time/response curve) indicating that the fasting TG 
concentration was an important determinant of the 
postprandial response. There was no postprandial 
change in serum TC in all subjects. However, the 
cholesterol levels of NIDDM and IGT patients were 
significantly higher than those of the normal 
subjects. There was also an increase in TRL TC in all 
subjects and then the cholesterol , concentration 
returned towards the fasting level. The TRL 
cholesterol concentrations of NIDDM and IGT patients 
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were higher than those of the normal subject at all 
times. The increase· in postprandial TRL cholesterol 
indicated there was an increase in cholesterol in the 
TRL fraction. Serum HDL-C decreased slightly in all 
subjects postprandially. The mean HDL-C level of 
normal subjects was significantly higher than those of 
the NIDDM and IGT patients. There was no significant 
changes in serum Apo A-I and Apo B in all subjects 
following the oral lipid loading. The mean Apo A-I of 
normal subjects was significantly higher than those of . 
NIDDM and IGT patients while the mean Apo B of the 
normal subjects was significantly lower than those of 
NIDDM and IGT patients. 
In the present study Maxolon was shown to be able 
to shorten the duration of an oral lipid loading test. 
There was abnormali ty in lipid, apolipoprotein and 
lipoprotein metabolism in NIDDM and IGT patients as 
revealed by altered concentrations of serum and TRL 
lipids, apolipoproteins and lipoproteins as compared 
with normal subjects. 
-8-
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1.1. Clinical biochemistry of lipids, lipoproteins and 
apolipoproteins 
1.1.1. Lipide: definition and physiological importance 
The lipids are a heterogeneous group of compounds 
related in metabolism to fatty acids. They are 
relatively insoluble in water and soluble in organic 
solvents. Lipids are essential because of their high 
energy value and are also important for fat-soluble 
vitamin absorption. The major lipide of the body are 
triglyceride, cholesterol and its esters, 
phospholipids and glycolipids. The triglyceride in 
adipose tissue is the major energy reservoir of the 
body. Many structural components of membranes contain 
lipids. Cholesterol is the precursor of steroid 
hormones and bile acids [1] 
1.1.2. Lipoproteins and apolipoproteins 
In the blood stream, lipids are transported as 
soluble protein complexes called lipoproteins. These 
consist of a non-polar core of triglyceride and 
. cholesterol ' esters coated with phospholipids, 
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cholesterol and specific proteins called 
apolipoproteins. Lipoproteins isolated by density 
gradient ultracentrifugation are classified in order 
of increasing density as • • (1) chylomicrons (d < 
0.95), (2) very-low density lipoproteins ( VLDL, d = 
0.95 - 1.006 ), (3) intermediate-density lipoproteins 
( IDL, d = 1.006 1.019 ), (4) low-density 
lipoproteins ( LDL, d = 1.019 - 1.063 ) and (5) high-
density lipoproteins ( HDL, d = 1.063 - 1.21 ). HDL 
can be further divided into HDL2 ( d = 1.063 - 1.125 ) 
and HDL3 ( d = 1.126 - 1.210 ). Apolipoproteins are 
the protein components of lipoproteins. The major 
plasma apolipoproteins are listed in table A. Some 
apolipoproteins are important in the synthesis and 
release of lipoproteins, while others are activators 
of plasma enzyme systems and provide recognition sites 
for cell receptors which are important in lipoprotein 
catabolism. 
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1.1.3. Lipoprotein metabolism 
1.1.3.1. Digestion and absorption of lipids 
About 100 gof triglyceride and about 1 g of 
cholesterol are ingested each day. Almost all of the 
triglyceride is absorbed, while only about half of the 
cholesterol is taken up. Normally no significant fat 
digestion occurs in the stomach. Fat digestion begins 
in the small intestine. Bile salts, lecithin and 
monoglyceride exert a detergent action, lowering 
surface tension and help to promote emulsification of 
lipids. Pancreatic lipase acts on emulsified fats and 
hydrolyzes the triglyceride to diglyceride and 
monoglyceride with release of the associated fatty 
acids. Most of the dietary cholesterol is in the form 
of cholesterol esters which are hydrolyzed in the 
intestinal lumen by the pancreatic cholesterol 
esterase to form cholesterol and fatty acids. After 
the contraction of the gallbladder, the concentration 
of bile salts in the intestine is high and lipids and 
bile sal ts interact to form micelles. The micelles 
move down their concentration gradient through the 
unstirred water layer to the brush border of the 
mucosal cells. The lipids enter the cells by passive 
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diffusion and are rapidly esterified inside the cells. 
Within the enterocyte, the absorbed monoglyceride and 
fatty acids containing more than 14 carbon atoms are 
re-esterified to triglyceride. Some of the 
triglyceride are formed from glycerophospha te. The 
absorbed cholesterol is re-esterified by the action of 
the enzyme acyl Coenzyme A: cholesterol 
acyltransferase. · Almost all the absorbed cholesterol 
is incorporated with reconstituted triglyceride into 
chylomicrons that enter the circulation via the 
lymphatics [2]. 
1.1.3.2 Exogenous lipoprotein metabolism 
Shortly after secretion, the triglyceride-rich 
chylomicrons acquire apo CII and apo E from HDL. Apo 
CII activates lipoprotein lipase, an enzyme attached 
to the luminal surface of the endothelial cells that 
line capillaries of adipose and muscle tissue. 
Lipoprotein lipase , hydrolyzes the chylomicron 
triglyceride to free fatty acids and mono- and di-
glycerides for energy production and storage. As the 
triglyceride core is depleted, the chylomicron shrinks 
and becomes a so called "chylomicron remnant". During 
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the catabolism of the chylomicron, some of the 
lipoprotein surface material, primarily phospholipids, 
cholesterol is transferred to HOL. Apo AI and the apo 
C protein family are also transferred to HDL. Some HDL 
constituents, apo E and cholesterol ester · are 
transferred to chylomicrons. The residence time of the 
chylomicron in the plasma governs the extent of this 
process. Little cholesterol ester will be transferred 
to the chylomicron if the chylomicron clearance is 
rapid. Chylomicron remnants that contain apo Band E 
are then taken up by apo Band E receptors in the 
liver where their constituents are catabolized [3]. 
1.1.3.3. Endogenous lipoprotein metabolism 
The endogenously made cholesterol esters and 
triglyceride by the liver are transported by VLDL to 
other si tes such as the adipose tissue and muscle. 
Triglyceride is synthesized from carbohydrates and 
fatty acids. Apo B is essentially apo 8-100 
synthesized by the liver. Shortly after secretion the 
VLDL acquire apo E and apo Cll from HDL. LDL in tissue 
capillaries hydrolyzes the VLDL which are converted to 
IDL and finally LDL as the sizes of VLDL particles 
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diminish and their densities increase. When the IDL 
are converted to LDL surface material from IDL 
including some phospholipid, free cholesterol, the 
majority of the ell and E apolipoproteins are 
transferred to HDL. LDL contains almost exclusively 
apo 8-100. The free cholesterol in the HDL particles 
in esterified by the LCAT enzymes, which is activated 
by apo AI. This n'ewly synthesized cholesterol ester is 
then transferred back to the IDL particles from HDL. 
Normally there is little IDL in the plasma. Some of 
the IDL are rapidly converted to LDL which are 
composed mainly of cholesterol ester in the core and 
apo B at the surface. IDL that are not converted to 
LDL are taken up by the liver via LDL receptors. LDL 
are taken up by extra-hepatic cells and by the liver 
where they bind to high-affini ty receptors on the 
plasma membrane and are then internalized. LDL are 
mainly responsible for transporting cholesterol from 
the liver to , peripheral tissues [3]. 
1.1.4. Dyslipoproteinaemia and atherosclerosis 
1.1.4.1. Risk factors associated with atherosclerosis 
Besides plasma lipid abnormalities several factors 
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are associated with increased risk of atherosclerosis 
such as age, sex, hypertension, smoking, etc. The risk 
of atherosclerosis increases with age and the risk of 
atherosclerosis is greater in men than in women. The 
exact mechanism ' of the lower incidence of 
atherosclerosis in ·women is uncertain, it may be 
related to higher triglyceride levels in men [4]. 
Atherosclerosis is often associated with and 
accelerated by hypertension. The relative risk of 
atherosclerosis in ,hypertensive smokers is much 
greater than normotensive non-smokers [5]. 
1.1.4.2. Cholesterol, lipoproteins and atherosclerosis 
Epidemiological studies of various populations have 
shown the importance of plasma cholesterol as a 
precursor of atherosclerosis [6]. There is a positive 
correlation between plasma cholesterol concentration 
and increased risk of atherosclerosis. This 
correlation is due to ~he atherogenic effect of plasma 
cholesterol. Cholesterol has been shown to be the 
principal lipid ingredient of the atherosclerotic 
lesion [7]. The relationship b~tween serum cholesterol 
and atherosclerosis is not a threshold one but is 
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proportional to the plasma cholesterol concentration 
within the population, the risk rising with the 
cholesterol value (8]. LDL is the major cholesterol 
carrier in the plasma, a high concentration of LDL-
cholesterol ( LDL-C ) in plasma is the most prevalent 
and most essential condition associated with 
accelerated atherogenesis. LDL-C concentration is 
directly associated with atherosclerosis [9]. It has 
been established that lowering definitely elevated 
blood cholesterol levels ( specially, blood levels of 
LDL-cholesterol ) will reduce the risk of heart 
attacks caused by coronary heart disease [10]. Another 
major cholesterol carrying component in the plasma is 
the HDL which usually carry about 20-25% of the 
cholesterol in the plasma. HDL-cholesterol ( HDL-C ) 
concentrations are strongly but inversely associated 
with cardiovascular disease the higher 
concentrations of HDL-C correlate with less 
cardiovascular disease and fewer cardiovascular events 
[11]. HDL plays an important role in the removal of 
'cholesterol from tissues possibly including the 
arterial wall [12], and could be the mechanism whereby 





1.1.4.3. Plasma triglyceride (TG) and atherosclerosis 
The status of plasma TG concentration as a risk 
factor for atherosclerotic disease is still 
controversial despite the association between plasma 
TG and coronary heart disease. It has been proposed 
that the association may be explained by the 
connection of high TG to other known risk factors, 
such as hypercholesterolaemia or reduced HDL-C, and 
not to elevated TG per se [13]. However, there is 
accumulation of evidence demonstrating that persons 
with hypertriglyceridaemia have an increased tendency 
to develop ischaemic heart disease, independent of 
other known risk factors [14,15]. It is possible that 
certain groups may be vulnerable to an atherosclerotic 
effect of hypertriglyceridaemia. Hypertriglyceridaemia 
may be a causal risk factor in women but not in men 
[16]. TG has also been found to be a stronger 
predictor of CHD in men with relatively low levels of 
plasma cholesterol [1'7]. 
1.1.4.4. Apolipoprotein A-I (apo A-I), apolipoprotein 
B (apo B) and atherosclerosis 
Although about 14 apolipoproteins are recognized, 
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only apo A-I and apo B have . been considered for 
routine quantitation. Apo A-I is the main structural 
protein in HDL and apo B comprises 95% of the 
apolipoproteins present in LDL. It is not surprising 
to find an inverse relationship between apo A-I level 
and atherosclerotic cardiovascular risk, and a direct 
relationship between apo B level and risk [18-20] 
because similar relationships were found in BDL, which 
carries most plasma apo A-I, and LDL which carries 
most apo B. The concentrations of apo A-I and apo B, 
or their ratio may be more ·useful indices than the 
lipid or lipoprotein-lipid concentrations [21]. It has 
been shown that apo A-I/ apo B ratio is better 
correlated with the severity and extent of coronary 
artery stenosis than LDL-C/ HOL-C or HOL-C/ total 
cho1esterol ratio [22]. The clinical use of plasma apo 
A-I & apo B measurements for the assessment of CHD 
risk is relatively new but shows great promise. 
1.1.4.5. Postprandial lipidaemia and atherosclerosis 
It has been suggested that atherosclerosis may be 
a postprandial phenomenon [23J. Postprandial 
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lipidaemia is due to the presence of triglyceride-rich 
lipoproteins ( TRL ) which include chylomicrons, VLDL 
and their remnants. It has been suggested that the 
interaction of TRL with arterial lipoprotein lipase 
constitutes an atherogenic process [24,25). Fasting 
elevations of TG may also be associated with impaired 
postprandial handling of TRL [24]. The liver and 
intestine both produce TRL. The liver secretes VLDL in 
response to a caloric load, whereas the intestine 
produces chylomicrons in the presence of dietary fat. 
Chylomicrons may be atherogenic in several 
circumstances [23]. Chylomicrons carry most of the 
dietary cholesterol and their initial degradation 
takes place in contact with the vascular endothelium. 
The chylomicrons and the{r remnants can be taken up by 
cells of the vessel wall, including monocyte-derived 
macrophages, and these interactions are associated 
with cholesterol accumulation. If there are higher 
postprandial levels of chylomicrons or their remnants 
and if these lipoproteins remain in the plasma for 
longer than normal, increased amounts of cholesterol 
may be delivered to the artery wall. In states of 
reduced LPL activity, such as in diabetes mellitus, 
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the chylomicrons may stay in the plasma for longer 
periods of time. As VLDL compete with chylomicrons for 
LPL [26] the residence times of chylomicrons would 
increase whenever the VLDL levels were elevated. The 
·plasma levels of chylomicrons and their remnants might 
of course increase simply due to intake of foods very 
high in saturated fats and cholesterol. Such diets 
will increase hepatic VLDL production which will lead 
to competition between VLDL and chylomicrons for LPL 
and also suppress LDL receptors, which will reduce 
hepatic clearance of chylomicron remnants. Normally 
VLDL may not be atherogenic as they carry relatively 
small amounts of cholesterol and they are relatively 
large and thus difficul t to penetrate through the 
arterial intima. However, VLDL from hyperlipidaemic or 
diabetic patients are functionally abnormal [27] and 
are unusually prone to deposit lipids in fibroblasts, 
endothelial cells, and macrophages [28,29]. Some 
species of VLDL ( -particularly those enriched in 
cholesterol and apolipoprotein E ) are readily taken 
·up into macrophages, converting them into foam cells 
in vitro (30]. Thus, even if normal VLDL are not 
atherogenic, those from hyperlipidaemic or diabetic 
patients may be. 
-28-
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1.2. Lipid Metabolism in diabetes mellitus 
1.2.1. Definition and classification of diabetes 
mellitus 
Diabetes mellitus is a clinical syndrome 
characterized by hyperglycaemia, due to deficiency or 
diminished effectiveness of insulin. It has been 
defined by the World Health Organization ( WHO )[31] 
as a fasting plasma venous glucose conc. greater than 
7.8 mmol/L or a conc. of 11.1 mmol/L or more two hours 
after a carbohydrate meal or two hours after a 75g 
oral glucose load. The WHO classification divides 
diabetes mellitus into insulin-dependent diabetes 
mellitus ( lOOM) and non-insulin dependent diabetes 
melli tus ( NIOOM ). In lOOM there is virtually no 
insulin secretion. In NIOOM either insulin is secreted 
in insufficient amount or there insensitivity to its 
actions. The state of impaired glucose tolerance (IGT) 
is defined by the WHO as a glycaemic . response to a 
. standard glucose load intermediate between normal and 
diabetes. Th~ fasting plasma venous glucose 
concentration lies between 5.5 and 7.8 .mmol/L and/or 
with a two-hour postprandial plasma glucose 
concentration between 7.8 and 11.1 mmol/L. Certain 
individuals may develop diabetes mellitus later. 
-29-
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1.2.2. Lipid metabolism in non-insulin dependent 
diabetes mellitus ( NIDDM ) 
NIDDM is the most common form of human diabetes; 
this is also known as Type 11, maturity onset, or non-
ketotic diabetes [32,33]. Abnormalities in lipoprotein 
metabolism are a prominent feature of the diabetic 
syndrome [34,35], and it is quite possible that the 
abnormal lipid metabolism contributes significantly to 
the increased morbidity and mortality from vascular 
diseases that characterize NIDDM [36]. 
NIDDM is characterized by tissue resistance to 
insulin whose major function is to facilitate the 
conversion of dietary carbohydrate to stored fat. The 
process involves the transfer of VLDL TG synthesized 
in the liver from gut-derived glucose ( or lactate ) 
via plasma to adipose tissue. Consequently, when there 
is insulin lack, or insulin resistance the abnormal 
lipoprotein metabolism results in hyperlipidaemia in 
one form or another • . The most common abnormality is 
increased plasma TG concentration [34,35,37,38}, and 
this is primarily due to increase in VLDL 
concentration [39]. The elevation of VLDL may result 
probably from abnormalities involve a combination of 
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an overproduction of VLDL TO and a defect in clearance 
of VLDL TG [40,41]. The hyperinsulinaemia associated 
with insulin resistance may directly stimulates VLDL 
production and the relative insulin deficiency at the 
cellular level associated with insulin resistance may 
also lead to VLDL production [42] • Decreased 
fractional catabolic rates ( FCR ) have been observed 
in VLDL TO metabolism [43-45]. As glycaemia decreased 
this decreased FCR increased showing the diabetes-
induced effect on VLDL clearance [46,47,48]. 
Overproduction of VLDL may saturate the catalytic 
sites on lipoprotein lipase therefore leading to 
slower clearance. The decrease in VLDL clearance is 
most likely due to reduced lipoprotein lipase activity 
[39]. It is not clear whether the deficiency of 
lipoprotein lipase in NIDDM is due to the al tered 
secretion of insulin or is a reflection of the insulin 
resistance. 
Another abnormality in plasma lipoprotein 
concentration most commonly seen with an increase in 
.VLDL-TG is a decrease in HDL-C levels ,[49,50]. The 
transfer of surface components of TRL to HDL by the 
hydrolytic ·action of lipoprotein lipase tends to be 
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low resulting in low HDL levels and 
hypertriglyceridaemia [51]. The activity of hepatic 
lipase which is important in HDL metabolism seems to 
be elevated in NIDDM patients [47]. The production of 
HDL has also been showed to be decreased in NIDDM 
[52] • 
1.3. Lipid tolerance test 
1.3.1. General discussion 
As most time of the day is in the postprandial 
state the abnormality in lipoprotein metabolism may be 
best studied after a meal. The absorption and 
transport of dietary fat lead to large changes in 
plasma lipoproteins [53,54] which include the newly 
synthesized, triglyceride-rich particles (chylomicron) 
[55] and also other lipoproteins such as HDL [56) 
which result from the metabolism of chylomicrons. The 
changes in the d ( . 1.006 fraction ( containing 
chylomicrons, chylomicron remnants and VLDL ) and in 
· the HDL after a fatty meal may reflect the exchange of 
lipid and apolipoprotein components between the plasma 
lipoproteins. The changes in the plasma lipoproteins 
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in the postprandial state are quite different in 
different individuals, and delicate abnormalities of 
plasma lipoprotein metabolism may be discovered in the 
postprandial state. Since the metabolism of dietary 
fat is mediated by plasma lipoproteins [53,54] and 
also because lipoproteins derived from the intestine 
have been found to be involved in the development of 
atherogenesis [231, lipoprotein metabolism may be 
better investigated in the postprandial state. 
Most of the studies of postprandial lipoproteins in 
human measure the sequential changes in the plasma 
after single or multiple fat loads. Triglyceride may 
be given as corn oil [57], soyabean oil [58] or cream 
[59] incorporated into a meal The usual dose is 0.5 -
3.0 9 triglyceride/ kg body weight. The presence of 
carbohydrate or protein in the meal may affect the 
metabolism of triglyceride. Vitamin A has also been 
used to study postprandial lipoproteinaemia [60]. 
1.3.2. · Use of Maxolon 
In studying the changes in lipids 'after an oral 
fat load the time between the ingestion of fat and the 
peak in plasma triglyceride usually occurs about three 
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to five hours after ingestion of oral fat. This 
variability results . primarily from differences in 
gastric emptying rate. It is necessary to take blood 
samples hourly in order to catch the peak in plasma 
triglyceride. Maxolon (metoclopromide hydrochloride) 
is a substituted benzamide which stimulates the 
motility of the upper gastro-intestinal tract without 
affecting gastric acid secretion [61]. Maxolon is used 
in the treatment of some forms of nausea and vomiting 
such as that associated with cancer therapy or that 
following surgery. Maxolon is also used for gastro-
oesophageal reflux or gastric stasis. Maxolon may be 
used to stimulate gastric emptying during radiographic 
examinations. Maxolon increases gastric peristalsis 
and relaxes the pyloric canal thus shortening the 
gastric emptying time [62,63]. It was used in the 
present study to see whether it was possible to 
shorten and standardize the duration of the lipid 
loading test. 
1.4 Objectives 
One of the effects of Maxolon is the stimUlation 
of gastric emptying. This is due to 'the fact that 
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Maxolon is able to increase gastric perist~lsis and to 
relax the pyloric canal. Theoretically, with the help 
of Maxolon an oral lipid load will be absorbed more 
quickly. IntralipidR is usually used in the intravenous 
lipid loading test but has never been used orally. In 
the present study the effect, if any, of 'Maxolon in 
shortening and standardizing the duration of an oral 
lipid loading test using IntralipidR was studied. 
Patients wi th NIDDM and IGT are associated wi th an 
increased risk of atherosclerosis-related vascular 
disease. As there is growing evidence that 
postprandial lipidaemia is important in atherogenesis, 
the degree of postprandial lipidaemia in patients with 
NIDDM or IGT and normal non-diabetic subjects was 




2. Materials and methods 
2.1 Materials 
Sodium chloride, density = 1.006 glmL: 8.5 grams of 
sodium chloride was dissolved in about two hundred mL 
of distilled water and then made up to one litre with 
distilled water. The density was checked with a 
refractometer, AO Scientific Instruments, . Model No. 
10408. 
Intralipid', 1 O!fr:fat emulsion for intravenous 
nutrition, was purchased from KabiVitrum, Stockholm, 
Sweden. 
Haxolon ( Hetoclopramide HCl ): was obtained from 
Beecham in ampoule containing 10 mg in 2 mL. 
Polyethylene glycol 6000: 50 9 PEG 6000 and 3.75 g 
glycine were first dissolved in 200 mL distilled 
water. pH was adjusted to 10 with 10 mol/L NaOH and 
then made up to 250 mL with distilled water. 
Cholesterol reagent: . was obtained from Baker 
Instruments, catalogue no. 27-017-680-009. 
Triglyceride reagent: was obtained from Baker 
Instruments, catalogue no. 27-017-375-000. 
Apolipoprotein A-I reagent and Apolipoprotein B 
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reagent: were obtained from Beckman Instruments, Inc. 
PIN 449300 and 449310 respectively. 
Quick-Seal'K Centrifuge Tubes, Tube Topper and Tube 
Slicerl were obtained from Beckman Instruments, Inc. 
PIN; 289-344329, 348140 and 303811 respectively. 
2.2. Subjects and patients 
2.2.1. Healthy subjects. thirteen healthy adults, six 
males and seven females, ranging in age of 21-38 years 
participated in the .Maxolon study. They were medical 
students or laboratory personnel who had no known 
systemic disease. The absence of IGT was confirmed by 
OGTT. 
2.2.2. NIDDM patients. Nineteen out-patients, five 
males and fourteen females, of 26 to 39 years of age 
were studied. The duration of NIDDM was from 1 to 2 
years. All the patients were considered diabetic 
(fasting plasma glucose levels> 7.8 mmol/L) by World 
Health Organization (WHO) criteria. ' 
2.2.3. IGT patie~ts. Fourteen out-patients, two males 
and twelve females, aged 26 to 40 years. No patient in 
-37-
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the group with IGT would be considered diabetic by WHO 
cri teria. Their fasting plasma glucose values were 
less than 7.8 mmol/L. However, the two-hour plasma 
glucose levels after 75 g of glucose taken orally were 
in the range 7.8-11.1 mmol/L. 
2.2.4. Study design 
Every normal subject was studied twice, with and 
without maxolon injection. The subjects were given the 
fat emulsion, 10% IntralipidR after a 12-hourovernight 
fast. The volume of fat emulsion taken contained O.5g 
fat/kg body weight. An indwelling catheter was 
inserted into an antebrachial vein and was used both 
for Maxolon ( Metoclopramide ) injection and blood 
sampling. The catheter was kept patent with citrate 
buffer as anticoagulant. Fifteen mL of blood were 
obtained immediately before ingestion of the 
IntralipidR and hourly for 5 hours ( with Maxolon 
injection ), or for 6 hours ( without Maxolon 
injection ). All the NIDDM and IGT patients were 
studied with Maxolon injection only. 
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2.3 Blood samples 
2.3.1. Serum samples 
Blood was collected in tubes without 
anticoagulant and was allowed to clot for about one 
hour. Serum was seperated from blood clot by 
centrifugation, 3000 rpm for 15 minutes at 4°C. All 
the samples were stored at 4°C and were analyzed 
within 24 hours. 
2.3.2. Triglyceride-rich lipoproteins (TRL) 
Five ml of serum from each subject were pipetted 
into a.Quick-SealTII Centrifuge Tube. The tube was 
filled up with sodium chloride of density 1.006 g/L 
and then sealed with a tube topper. TRL were isolated 
from all serum samples by a single ultracentrifugal 
spin ( 49,000 rpm, .16 hour, 4°C ) at density 1.006 
g/ml in a Beckman Type 70-Ti rotor. The tubes were 
then cut at the 5 ml level with a tube slicer. The 
upper TRL fractions were aspirated into a 3 m! 
graduated test tube and adjusted to a final volume of 
1.5 m! wi th normal saline. TRL fractions were not 
recentrifuged. Samples were aliquoted and stored at 
4°C and were analyzed within 24 hours. 
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2.4. Analytical methods 
2.4.1. Cholesterol 
Serum and TRL cholesterol were assayed 
I 
enzymatically for total cholesterol on a Cobas-Mira 
analyzer using Baker reagent. Cholesterol esterase 
(CE) catalyzes the hydrolysis of cholesterol esters to 
free cholesterol ' and fatty acids. The cholesterol is 
then oxidized in the presence of cholesterol oxidase ' 
(CO) to cholesten-3-one and hydrogen peroxide. 
Formation of a quinoneimine from hydrogen peroxide, 4-
aminoantipyrine, and phenol is catalyzed by peroxidase 
(HPO). The absorbance at 520 nm of the quinoneimine 
produced is directly proportional to the amount of 
total cholesterol in the sample. Coefficient of 
vari~tion of 1.·1% and . 2.4% were obtained for within-
day and between-day at a level of 7.81 mmol/L. 
2.4.2. Triglyceride 
Serum and TRL fractions were assayed for 
·triglyceride on a Cobas-Mira analyzer using Baker 





system. The Trinder reagent incorporates the coupling 
of 4-aminoantipyrenewith 2,4-dichlorophenylsulfonate 
to form a red quinonimine compound wi th a maximum 
·absorbance at 510 nm. Coefficient of variation of 0.6% 
and 1.7" were obtained for within-day and between-day 
precision respectively at a level of 1.47 mmol/L. 
2.4.3. HDL-cholesterol 
HDL-cholesterol of serum was determined after 
separation from other ~holesterol fractions, ie, LDL 
and VLDL by precipitating the latter two using 
polyethylene glycol 6000 (PEG precipitating reagent). 
Two hundred pL PEG precipitating reagent was added to 
equal volume of serum in a Khan tube. After mixing on 
a vortex mixer the mixture was allowed to stand at 
room temperature for 30 minutes, then centrifuged at 
2000 g for 10 minutes. The supernatant was removed and 
assayed for cholesterol concentration. Coefficient of 
variation of 1.6% and 5.4% .were obtained for within-
run and between-run precision respectively. 
2.4.4. Apo A-1 and Apo-B 
Serum samples were measured for Apo . A-1 and Apo B 
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by rate immunonephelometry using the Beckman . Array 
Protein Analyzer. The rate of increase in light 
scattered from particles suspended in solution as a 
result of complexes formed during an antigen-antibody 
reaction was measured. Coefficient of variation values 
of < 5% were obtained with the Apo A-I and Apo B 
measurements for within-run precision and of < 8% for 
between run precision. 
2.5. Measurement of postprandial increase in serum and 
TRL triglycerides 
Area measurement was made for each timet response 
curve. The area between the curve and baseline (zero 
concentration) was calculated manually using the 
trapezoid rules. 
2.6. Statistical analysis 
Values were expressed individually or as mean ± 
SEM. Statistical analysis was carried out with Abstat" 
software. Paired and unpaired t-tests were used to 
compare differences between means. Pearson correlation 
coefficient (r) was computed to identify significant 
correlation between lipid variables. Two-way analysis 
, -42-
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of variance was used to determine if there was any 
change on postprandial lipid variables. A p value less 
than 0.05 was considered as significant. 
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3. Results 
Serum cholesterol, triglyceride, DOL-cholesterol, 
apolipoprotein A-I, apolipoprotein B, TRL cholesterol 
and TRL triglyceride were measured at 0, 1, 2, 3, 4, 
5 hours with Maxolon injection and also at 6 hour for 
normal subjects without Maxolon injection. Tables 1 to 
4 show the results of each analyte for nor~al subjects 
( with Maxolon injection ), normal subjects ( without 
Maxolon injection ), NIDOM patients and IGT patients 
respecti vely. Tables 5 to 8 show the mean ± SEM 
concentration of each analyte for normal subjects 
(with Maxolon injection), normal subjects (without 
Maxolon injection), NIDOM patients and IGT patients, 
respectively. 
Triglyceride 
All the normal subjects had fasting serum TG 
within the reference range (0.63 ± ~.05 mmol/L). The 
serum TG concentration rose after the oral lipid 
loading. With Maxolon injection the mean TG rose 76.2 
% and peaked at two hours ( Figure 1 ). The time for 
-44-
Table 1. Serul cholesterol, triglyceride, RDL cholesterol! Apo A-I and Apo B 
. concentrations, and concentrations of cholestero and trlglycerlde in 
. triglyceride-rIch lipoprotein fraction (TRL) in 13 norlal subjects 
before and after the oral lipid loading with Kaxolon injection 
U 1.01/1 t Igldl 
--------------~----------~---------.--------------------------~----------------~-Subject SeruI: TRL: 
Rour Chol t * TGu RDL-Cu Apo A-I t Apo Bt Chol tA ,GAt 
---------------------------------------------------------------------------------No.l 0 4.70 0.63 0.88 89.1 74.3 0.12 0.20 
1 4.75 0.95 0.73 91.6 75.2 0.12 0.41 
2 4.70 1.34 0.80 87.6 75.8 0.12 0.93 
3 4.75 l.U 0.84 91.7 75.8 0.16 1.01 
4 4.97 1.22 0.78 91.8 76.6 0.16 0.74 
5 4.94 0.81 0.83 90.5 75.7 0.13 0.33 
-------------------------------------~-------------------------------------------10.2 0 3.87 0.68 1.61 155 31.2 0.22 0.36 
1 3.76 0.68 1.66 166 31.9 0.17 0.37 
2 3.64 1.27 1.59 164 30.6 0.27 0.91 
3 3.66 1.11 1.52 162 30.4 0.24 0.77 
~ . 4 3.76 1.49 1. 45 165 31.6 0.30 1.14 5 3.64 0.89 1.55 161 30.7 0.21 0.58 
-----------.-----------~---------------------------------------------------------10.3 0 4.04 0.34 1.08 89.1 54.2 0.08 0.10 
1 4.13 0.98 1.16 97.0 54.8 0.11 0.54 
2 4.06 1.05 1.14 98.0 53.1 0.12 0.65 
3 3.89 0.93 1.06 93.7 53.7 0.10 0.61 
4 l.91 0.70 1.12 98.3 54.0 0.12 0.l9 
5 3.97 0.40 1.10 99.8 54.7 0.08 0.15 . 
--------------------------------------------------------------------------~------No.4 0 5.86 1.08 0.82 121 94.4 0.34 0.63 
1 6.02 2.11 0.94 129 96.4 0.44 1.52 
2 5.38 1. 95 0.90 116 92.0 0.44 1.40 
J 5.83 1.81 0.76 125 92.6 0.38 1.22 
4 5.35 1.13 0.84 120 92.9 0.28 0.65 
§ 5.46 0.94 0.84 118 96.9 0.21 0.48 
---------------------------------------------------------------------------------10.5 0 4.81 0.88 1.36 160 66.6 0.22 0.51 
. 1 3.96 1.10 1.46 158 66.2 0.19 0.63 
2 4.85 1. 95 1.40 166 68.0 0.20 1.46 
3 4.51 1.54 1.32 153 68.0 0.20 1.24 
4 4. 73 1.08 1.32 157 66.7 0.16 0.64 
5 4.83 0.67 ·1.38 153 66.5 0.11 0.29 
----------------------------------------------------------------~---------------~ 10.6 0 6.33 0.51 2.24 212 78.9 0.06 0.18 
1 6.43 0.58 2.32 216 79.6 0.06 0.21 
2 6.41 0.72 2.34 209 79.3 0.06 0.39 
3 6.28 0.66 2.21 202 78.7 0.06 0.34 
4 6.29 0.43 2.36 204 78.4 0.06 0.16 




Table 1 continued. 
------------------~--------------------------------------------------------------
, Subject Seru.: TR~: 
Hour Chol** TGu RDL-Cti Apo A-It Apo Bt Cbol it TG** 
---------------~---~-------------------------------------------------------------10.7 0 4.04 0.49 1. 70 223 58.5 0.11 O.U 
1 4.14 0.61 1.16 213 59.5 0.14 0.21 
2 4.22 1.20 1.68 206 58.4 0.19 0.49 
3 4.14 0.94 1.68 222 51.0 0.15 0.34 
4 3.98 0.62 1.10 220 57.1 0.08 0.16 
5 4.20 0.42 1.80 214 59.3 0.06 0.11 
---------------------------------------------------------------------------------10.8 0 3,.19 0.61 1.28 170 58.1 0.12 0.a2 
1 3.10 0.71 1.20 160 59.4 0.14 0.34 
2 3.67 1.00 1.22 162 59.4 0.16 0.69 
3 3.48 1.17 1.18 152 57.9 0.23 0.87 
4 3.60 1.04 1.18 158 59.4 0.22 0.68 
5 J.47 0.83 1.16 162 57.9 0.13 0.09 
--------------------------------------------------------------------~------------10.9 0 2.93 . 0.62 1.10 213 30.0 0.14 0.3f 
1 2.80 0.84 1.56 208 30.0 0.17 0.51 
2 3.02 0.71 1.52 216 30.0 0.16 0.43 
3 2.94 0.81 1.51 211 30.0 0.13 0.52 
4 2.91 0.64 1. 72 203 30.0 0.12 0.35 
5 2.96 0.58 1.68 215 30.0 0.10 0.29 
--------------------_.-----------------------------------------------------------No.10 0 4.21 0.73 1.52 222 53.3 0.11 0.38 
1 4.14 1.04 1.52 205 52.2 0.19 0.65 
2 4.21 1.04 1.50 209 53.2 0.22 0.69 
3 4.02 1.19 1.56 195 50.6 0.16 0.82 
4 4.05 0.94 1.50 199 50.1 0.16 0.60 
5 4.14 0.71 1.50 204 51.1 0.12 0.37 
---------------------------------------------------------------------------------No.11 0 4.14 0.48 2.14 198 52.3 0.06 0.16 
1 4.60 0.53 2.10 217 52.0 0.09 0.22 
2 4.61 0.58 2.16 208 52.5 0.06 0.28 
3 4.72 0.59 2.09 217 51.8 0.06 0.40 
4 4.71 0.96 2.07 218 52.3 0.09 0.51 
S 4.64 0.62 2.15 218 52.0 0.06 0.21 
---------------------------------------------------------------------------------10.12 0 3.13 0.54 1.22 166 43.7 0.12 0.21 
1 2.90 0.55 1.32 161 43.2 0.13 0.32 
2 3.03 0.96 1.20 161 41.2 0.13 0.68 
3 3.09 1.23 1.14 165 44.7 0.11 1.16 
4 2.84 0.73 1.20 159 41.9 0.12 0.47 
5 2.91 0.57 1.22 166 43.4 0.08 0.29 
----------------------~----------------------------------------------------------10.13 0 4.49 0.60 1.62 214 64.1 0.09 0.17 
1 4.41 0.64 1.68 200 64.7 0.11 0.29 
2 4.49 0.89 1.60 215 65.4 0.13 . 0.48 
3 4.23 0.49 1.62 205 63.7 0.06 0.12 
4 4.32 0.42 1.68 208 64.5 0.06 0.11 
5 4.32 0.41 1.58 210 62.3 0.06 0.09 
------------------------------------------------------------------------~--~---~-Abbreviations used: Chol - Cholesterol 
BDL-C - HDL-cbolesterol 
TG - Trigllceride 
TRL - trlg yceride-rich lipoprotein 
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Table 2. SeruI cholesterol, triglyceride, HDL cholesterol 1 Apo A-I and Apo B . 
. co~centra~ion8f and,concentrations qf cholest~ro and tr glyc~rlde iD 
. trIglycerIde-rIch lIpoprotein fractIon (TIL) In 13 norlal SUblects 
before and after the oral lipid loading without Kaxolon injec iOI 
u .10111 * Ig/dl 
---------------------------------------------------------------------------~-~---Subject SeruI: TRL: 
Hour Chol** TGu BDL-Ctt Apo A-It Apo Bt Cholu TGu 
---------~-----------------------------------------------------------------------10.1 0 4. 74 0.70 0.90 136 77.8 0.22 0.28 
1 4.47 1.01 1.00 136 77.7 0.23 0.51 
2 4.52 1.06 0.98 130 76.3 0.23 0.51 
3 4.71 1.12 0.84 140 76.4 0.24 0.57 
4 4.92 1.23 0.84 139 80.8 0.25 0.63 
5 4.85 1.32 1.02 142 78.9 0.24 0.68 
6 4.65 1.14 0.90 138 76.3 0.22 0.51 
.....  
---------------------------------------------------------------------------------10.2 0 3.77 0.60 1.24 200 40.3 0.22 0.25 
1 3.80 0.65 1.16 197 39.2 0.18 0.28 
2 4.06 1.07 1.34 210 41.3 0.23 0.59 
3 3.74 0.88 1.06 193 39.3 0.22 0.41 
4 3.90 0.73 1.34 209 41.9 0.21 0.36 
5 3.95 0.69 1. 38 198 U.6 0.16 0.34 
6 4.05 0.60 1.34 215 41.7 0.13 0.24 
--------------------------------------------------------------------------------~ 10.3 0 l.45 0.50 0.86 139 52.2 0.08 0.16 
1 3.50 0.56 0.88 140 53.1 0.08 0.31 
2 3.14 0.65 0.84 132 50.9 0.09 0.31 
3 3.27 0.73 0.88 125 50.9 0.09 0.45 
4 3.13 0.98 0.82 127 48.4 0.08 0.69 
5 3.15 0.67 0.86 125 49.7 0.08 0.40 
6 3.30 0.49 0.82 127 50.1 0.08 0.21 
---------------------------------------------------------------------------------10.4 0 5.40 1.18 0.90 98.8 95.2 0.30 0.69 
1 5.19 1.25 .0.84 97.5 93.2 0.30 0.82 
2 5.00 1.95 0.82 94.0 88.9 0.33 1.51 
3 5.24 1.83 0.82 98.7 91.5 0.38 1.38 
4 4.90 2.02 0.84 98.8 92.3 0.38 1.51 
5 5.22 1.47 0.84 99.9 93.5 0.37 1.01 
6 5.17 1. 70 0.88 97.1 92.3 0.29 1.14 
---------------------------------------------------------------------------------10.5 0 4. 31 0.68 1.44 III 57.3 0.14 0.36 
1 4.13 0.89 1.46 129 57.1 0.12 0.61 
2 4.01 1.49 1.34 130 56.7 0.10 1.12 
3 4.22 1.28 1.40 132 56.8 0.10 1.08 
4 4.23 0.98 1.36 131 56.3 0.12 0.71 
5 4.39 0.59 1.50 132 58.2 0.08 0.27 
6 ·4.21 0.53 1.52 136 56.4 0.08 0.18 
---------------------------------------------------------------------------------10.6 0 6.13 0.54 2.26 205 78.4 0.06 0.15 
1 6.19 0.62 2.24 205 76.6 0.06 0.18 
2 6.23 0.72 2.24 201 78.3 0.09 0.42 
3 6.35 0.84 2.30 202 71.6 0.09 0.56 
4 6.23 1.02 2.24 200 76.6 0.06 0.68 
5 6.29 0.68 2.30 204 77.1 0.06 0.40 
6 6.39 0.52 2.32 197 76.7 0.06 0.21 
---------------------------------------------------------------~-----------------
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Table 2 continued. 
---------------------------------------------------------------------------------Subject SeruI: TIL: 
lour Chol u TGu DOL-Cu Apo A-I t Apo .1 Chol· 1 'GIt 
---------------------------------------------------------------------------------10.1 0 4.92 0.40 1.68 191 68.8 0.06 0.12 
1 4.57 0.51 1.56 190 63.9 0.06 0.18 
2 4.60 0.70 1.52 192 62.5 0.06 0.38 
3 4.54 0.51 1.50 198 64.9 0.06 0.20 
4 4.35 0.77 1.56 189 62.0 0.06 0.49 
5 4.53 0.50 1.52 . 185 62.4 0.06 0.22 
6 4.50 0.40 1.54 183 62.2 0.06 0.12 
---------------------------------------------------------------------------------10.8 0 3.95 0.55 1.48 183 51.9 0.08 0.18 
1 3.58 0.64 1.22 182 50.5 0.07 0.29 
2 4.15 0.78 1.50 197 53.7 0.09 0.35 
3 3.84 0.88 1.46 191 52.7 0.09 0.47 
4 4.18 0.13 1.66 223 59.1 0.08 0.29 
5 3.83 0.63 1.44 175 50.3 0.06 0.23 
6 3.89 0.66 1.44 171 50.9 0.06 0.22 
---------------------------------------------------------------------------------Ro.9 0 2.70 0.87 1.32 153 30.0 0.23 0.44 
1 2.72 0.88 1.34 153 30.0 0.21 0.46 
2 2.71 0.90 1. 34 151 30.0 0.26 0.49 
3 2.71 0.90 1.28 146 30.0 0.26 0.54 
4 2.87 1.02 1.34 ' 161 30.0 0.24 0.64 
5 2.89 0.93 1.40 160 30.0 0.10 0.58 
6 2.80 0.90 1.32 159 30.0 0.21 0.58 
----------------~----~--------------------------------------------------~--------10.10 0 4.32 0.66 1. 76 190 54.8 0.10 0.26 
1 4.42 0.79 1.68 189 54.2 0.11 0.40 
2 4.43 0.80 1.64 192 56.6 0.10 0.44 
3 4.30 0.84 1.56 182 53.5 0.11 0.44 
4 4.22 O.U 1.54 177 51.8 0.12 0.41 
5 4.22 0.90 1.60 176 52.4 0.13 0.51 
6 4.35 0.75 ·1.46 178 52.4 0.10 0.36 
---------------------------------------------------------------~-----------------10.11 0 4. 74 0.47 2.12 200 51.5 0.06 0.15 
1 4.70 0.55 2.10 221 50.8 0.06 0.18 
2 4.69 0.58 2.06 224 50.8 0.06 0.26 
3 4.50 0.18 2.02 215 51.0 0.08 0.40 
4 4.58 0.81 2.02 203 51.0 0.08 0.42 
5 4.58 0.89 2.02 218 51.0 0.10 0.53 
6 4.14 0.66 2.06 195 53.9 . 0.06 0.23 
---------------~------------------------------~----------------------------------10.12 0 3.28 0.55 1.14 150 41.4 0.10 0.26 
1 , 3.11 0.61 1.06 145 39.0 0.08 0.27 
2 3.19 0.65 1.04 141 41.1 0.09 0.34 
3 3.14 0.71 1.02 149 39.9 0.10 0.41 
4 3.10 1.19 1.08 142 38.7 0.06 0.93 
5 3.21 1.05 1.10 143 39.1 0.09 0.70 
6 3.25 0.70 1.12 149 40.3 0.09 0.36 
---------------------------------------------------------------------------------Ro.13 0 3.94 0.52 1.66 169 50.0 0.06 0.16 
1 4.01 0.54 1.68 168 50.3 0.08 0.19 
2 3.80 0.72 1.58 167 49.9 0.09 0.33 
3 3.94 0.94 1.64 161 48 .8 0.06 0.50 
4 4.02 0.55 1.56 160 47.9 0.06 0.21 
5 4.03 0.54 1.64 165 47 .2 0.06 0.21 
6 l.'7 0.37 1.58 165 47.2 0.06 0.11 
----------------------------------~------------------------------~-----------.----Abbreviations used: Chol - Cholesterol TG - Tri91rceride 
HDL-C - RDL~cbolesterol TIL - trlg yceride-ricb lipoprotein 
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Table l. Serul cholesterol, triglyceride, HDL cholesterol! Apo A-I and Apo B 
concentrations, and concentfations of cholestero and triglrcerlde iD 
. triglyceride-rlcb lipoproteIn fraction (TIL) in 19 IIDDM pa lents 
. before and after tbe oral lipid loading with Kaxolon injection 
it 1101/1 t Ig/dl 
----------------------------~------------------.-----------~---~~----------------Subject Serul: TRL: 
Hour Cbol*t TGu HDL ... Cu Apo A-It Apo Bt Choltt 'l'Gu 
---~----------~--------------------------------.----------------------------------Jo.l 0 4.22 0.64 1.14 136 59.9 0.07 0.30 
1 4.26 0.90 1.18 143 59.8 0.10 0.48 
2 4.21 0.75 1.18 142 58.6 0.08 0.39 
3 4.14 1.04 1.16 136 57.2 0.11 0.69 
4 . 4,14 1.23 1.12 133 57.6 0.11 0.86 
5 4.25 0.77 1.12 146 60.0 0.08 0.37 
---------------------------------------------------------------------------------No.2 0 4.86 0.80 1. 94 199 52.3 0.26 0.53 
1 4.88 1. 38 1.96 203 52.9 0.27 0.92 
2 4.92 2.65 1. 94 210 53.2 0.24 2.01 
3 4.78 2.75 1.86 190 52.3 0.26 2.15 
4 4. 98 1.50 1.88 192 53.1 0.27 0.98 
5 4.87 0.95 1.90 203 53.8 0.25 0.55 
-----------------------------------------------------------------~---------------10.3 0 5.60 2.08 1. 23 167 91.8 0.65 1.43 
1 . 5.47 2.29 1.18 166 91.4 0.66 1.62 
2 5.41 3.72 1.22 161 91.6 0.67 2.90 
3 5.55 5.02 1.24 164 91.5 0.64 4.14 
4 5.49 3.01 1.18 164 91.0 0.67 2.05 5 5.56 2.25 1.20 162 91.4 0.69 1.49 
---------------------------------------------------------------------------------Ho.4 0 3.62 0.50 1.46 137 48.2 0.06 0.09 
1 3.68 0.57 1.42 139 U.3 0.06 0.11 
2 3.64 0.58 1.40 138 48.1 0.06 0.15 
3 3.63 0.70 .1.46 135 48.4 0.06 0.27 
4 3.56 0.49 1.44 132 48 .1 0.06 0.10 
5 3.58 0.46 1.44 139 48.0 0.06 0.08 
--------------------------------------------------------------------------~------10.S 0 5.70 1.21 1.04 171 93.4 0.22 0.59 
1 5.54 1.88 0.96 169 92.8 0.24 1.25 
2 5.61 2.12 0.98 170 93.9 0.35 1.43 
3 5.64 1. 83 1.02 167 92.4 0.33 1.11 
« 5.62 1.26 1.08 165 93.1 0.23 0.55 
5 5.86 1.17 1.00 113 92.7 0.26 0.44 
-------------------~-------------------------------------------------------------10.6 0 3.80 0.86 1.30 111 46.1 0.13 0.48 
1 '3.73 1.00 1.28 169 46.4 0.14 0.65 
2 3.64 1.36 1.28 167 45.2 0.19 0.96 
3 3.63 1.32 1.26 165 46.4 0.16 0.87 
4 3.65 1.03 1.26 167 46.7 0.15 ) 0.64 
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'able 3 continued. 
-----------------~-----------~--~---~----------------.------~---~-------~---------Subject Serua: TRL: 
ROllr tbol·· !GAt BDL-C" Apo A-I· Apo B' Chol·· !GU 
.---------------------------------------------------------------------------------10.7 0 5.90 1.25 1.20 197 94.7 0.32 0.86 
1 6.13 2.36 1.20 195 94.4 0.47 1. 72 
2 5.93 2.93 1.18 199 93.2 0.49 1.98 
3 5.93 3.17 1.20 199 93.9 0.54 2.25 
4 6.06 2.34 1.18 201 95.3 0.58 1.68 
5 5.97 1.l9 1.18 20l 95.5 0.34 0.83 
---------.~---~------------------------------------------------------------------Jo.8 0 •• Ol 0.50 1.16 163 60.9 0.09 0.2l 
1 3.94 0.53 1.14 167 57.0 0.06 0.32 
2 l.95 0.15 1.12 165 57.5 0.11 0.50 
3 4.11 0.68 1.14 169 58.0 0.13 0.44 
4 4.01 0.46 1.04 168 57.0 0.06 0.23 
5 4.10 0.34 1.16 163 60.3 0.06 0.01 
--------------------------------------------------------------.--~---------------10.9 0 4.99 0.94 1.14 149 73.4 0.13 0.50 
1 4.85 1.47 1.08 146 73.1 0.14 1.07 
2 4.73 1.07 1.06 143 75.4 0.15 0.68 
3 4.71 1.17 1.06 149 14.7 0.12 0.72 
4 4.73 1.19 1.04 143 73.9 0.11 0.74 
5 4.96 0.98 1.14 149 73.8 0.10 0.50 
----~----------------------------------------------------------------------------10.10 0 5.08 0.49 2.00 193 60.1 0.06 0.08 
1 4. 93 0.52 1. 94 196 60.8 0.08 0.15 
2 5.07 0.62 1.86 200 59.9 0.11 0.23 
J 4.89 0.64 1.80 196 57.9 0.12 0.20 
4 4.74 0.49 1.86 184 59.2 0.06 0.12 
5 4.83 0.41 1.88 183 56.7 0.06 0.07 
---------~--------~------------------------------------------------------ --------No.l1 0 5.02 2.24 0.90 142 82.0 0.56 1.24 
1 4.87 2.25 0.90 137 81.0 0.48 1.36 
2 5.01 3.34 '0.96 144 82.7 0.48 2.15 
3 4.75 4.36 0.86 140 80.0 0.59 3.02 
4 4. 97 3.77 0.88 140 82.7 0.80 2.71 
5 4.85 2.82 0.86 138 80.5 0.72 1.98 
---------------------------------------------------------------------------------10.12 0 5.68 0.62 1.32 158 88.4 0.06 0.10 
1 5.43 1.05 1.26 150 85.6 0.12 0.55 
2 5.57 0.81 1.22 155 86.6 0.09 0.31 
1 5.74 0.63 1.30 159 87.4 0.06 0.21 
4 5.63 0.46 1.34 158 85.3 0.07 0.08 5 5.64 0.46 1.40 153 86.7 0.06 0.08 
------------------~--------------------------------------~-----------------------10.13 0 ' 4.71 0.89 1.06 143 75.0 0.09 0.26 
1 4.66 0.96 1.04 134 73.6 0.15 0.39 
2 5.07 1.14 1.10 149 77.6 0.23 0.50 
3 4.70 1. 70 . 1.00 139 76.3 0.20 1.08 
4 4.68 1.87 1.10 137 73.2 0.30 1.16 




Table 3 continued. 
-----------------------------------~-------------------------~~------------------Subject Serua: . TRL: 
Hour Chol** 'l'Gu HDL-Cu Apo A-l* Apo a* Chol tt TGu 
--------------------------------------------------------~------------------------10.14 0 4.75 0.53 1.36 147 64.6 0.10 0.26 
1 4.76 0.79 1.38 150 65.7 0.14 0.47 
2 4.79 0.98 1.36 152 64.3 0.14 0.51 
3 4.76 1.20 1.38 152 63.1 0.25 0.85 
4 4.81 1.04 1.34 152 65.5 0.17 0.67 
5 4.74 1.18 1.36 152 64.1 0.19 0.71. 
---------------------------------------------------------------------------------10.15 0 4.68 0.62 1.36 146 64.2 0.08 0.24 
1 4.50 0.63 1.32 139 63.9 0.08 0.l2 
2 4.56 0.75 1.34 142 6S.6 0.09 0.39 
3 4.58 1.15 1.28 138 63.7 0.12 0.68 
4 4.59 0.76 l.lt 139 63.3 0.11 0.36 
5 4.70 0.74 1.36 146 65.0 0.08 0.34 
---------------------------------------------------------------------------------10.16 0 5.07 0.37 2.14 192 50.7 0.06 0.13 
1 4.97 0.64 2.18 185 49.4 0.06 0.35 
2 4.84 0.97 2.14 180 49.9 0.08 0.65 
3 4.97 0.58 2.18 186 50.6 0.06 0.29 
4 4.88 0.49 2.16 186 50.1 0.06 0.21 
5 4.80 0.38 2.12 183 49.8 0.06 0.11 
------------------------------------~--------------------------------------------10.17 0 1.95 0.68 0.86 114 66.9 0.20 0.10 
1 4.18 1.07 0.86 120 67.7 0.16 0.58 
2 4.08 1.55 0.82 116 66.8 0.20 1.01 
3 4.17 2.21 0.82 117 67.2 0.26 1. 46 
4 4.14 1.30 0.84 120 67.7 0.25 0.81 
5 . 4.10 0.72 0.82 119 67.9 0.14 0.34 
---------------------------------------------------------------------------------Ro.18 0 5.89 1.07 1.24 152 102 0.17 0.51 
1 6.02 1.48 .1.24 157 101 0.26 0.82 
2 5.92 1.69 1.26 154 103 0.33 1.05 
3 5.91 2.02 1.24 148 100 0.41 1.39 
4 5.63 2.38 1.18 145 101 0.42 1.5. 
5 6.00 2.18 1.20 139 101 0.49 1.45 
------------------------------------------------------------------------------.--10.19 0 5.85 1.87 0.90 124 116 0.55 1.2. 
1 5.56 1.88 0.90 125 115 0.49 1.38 
2 6.05 1.98 0.96 127 116 0.53 1.31 
3 S.91 2.54 0.90 129 114 0.57 1.91 
4 5.80 2.84 0.90 128 114 0.62 2.15 
5 5.86 2.35 0.90 123 115 0.60 1. 76 
--------------------------------------~---------------------------------------~-~ Abbreviations used: Chol - cholesterol TG - Triglrceride 
BDL-C - BDL-cholesterol TRL - trlg yceride-rich lipoproteiD 
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Ta'bIe •• SeruI choltsterol, triglyceridt, BDL choltsterolt Apo A-I and Afo B i 
, eoncentrat ofta, and concentrat one of cho estero and tr llYCer de n 
trigllceride-rlch lipoprotein fraction (TRL) in 14 IGT pa ients before 
and a ter the oral lipId loading with Kaxolon injection. 
u 1.01/1 * Ig/dl 
-------------------------------------------~-----------------~---------~-------~-. . Subject SeruI: TRL: 
Boor Chol** TGu DDL-Cu Apo A-I * Apo B* Chol** TGtt 
---------------------------------~-----------------------------------------------Ho.l 0 6.21 3.78 0.90 169 104 0.83 0.67 
1 6.23 3.90 0.94 168 105 0.86 0.69 
2 6.29 4.33 0.90 161 105 0.83 0.73 
3 6.30 •• 41 0.92 166 105 0.86 0.74 
4 6.46 5.05 0.94 164 107 0.91 0.80 
5 6i49 5.27 0.94 165 106 0.90 0.89 
---------------------------------------------------------------------------------10.2 0 5.70 0.89 1.64 161 73.4 0.20 0.50 
1 5.58 0.92 1. 74 162 74.4 0.11 0.52 
2 5.69 1.05 1. 74 161 74.4 0.19 0.62 
3 5.56 1.20 1.60 159 73.5 0.11 0.80 
t 5.59 1.38 1.58 158 74.6 0.18 1.00 5 5.58 1.11 1.60 160 74.1 0.17 0.66 
---------------------------------------------------------------------------------10.3 0 4.68 0.61 1.08 153 72.8 0.06 0.15 
1 4.37 0.83 0.98 159 73.4 0.08 0.39 
2 4.71 1.01 1.00 156 74.2 0.12 0.54 
3 4.33 1.18 1.00 151 72.2 0.16 0.10 
4 t. 74 0.87 1.10 155 13.6 0.10 0.41 
5 4.99 0.72 1.08 158 75.2 0.06 0.23 
--------------------------------------------------------------------------~-~----10.4 0 5.69 1.02 2.02 236 75.0 0.20 0.54 
1 6.24 1.16 2.16 225 76.5 0.19 0.61 
2 5.92 1.21 2.10 246 77.2 0.24 0.71 
3 6.12 1.43 2.06 234 73.5 0.23 0.85 
4 5.98 1.16 ·2.08 234 73.5 0.2) 0.69 
5 6.21 1.06 2.18 234 76.1 0.18 0.56 
---------------------------------------------------------------------------------10.5 0 5.95 1.65 1.32 179 102 0.33 0.63 
1 5.89 1.83 1.30 173 99.2 0.34 0.85 
2 6.03 2.15 1.20 173 98.5 0.41 1.25 
3 5.13 2.82 1.28 119 103 0.41 1..2 
4 5.72 2.84 1.14 171 99.0 0.50 1.89 
5 5.58 2.00 1.11 116 99.5 0.46 1.11 
---------------------------------------------------------------------------------10.6 0 5.57 1.69 1.08 152 94.9 0.49 1.00 
1 5.51 2.41 1.00 150 91.3 0.59 1.68 
2 '5.59 4.01 0.94 149 91.3 0.59 2.95 
J 5.71 3.05 0.90 149 89.4 0.57 1.97 




Table 4 continued. 
--------------~-------------~-----------------------~-~--------------------------Subject SeruI: TRL: 
Hour Chol t* TGB HOL-Cu Apo A-It Apo B* Chol*t TGu 
------------------------------.-------------------------------------------.--------
10.7 0 5.80 1.56 0.82 116 101 0.40 1.01 
1 5.52 1.63 0.86 118 98.2 0.40 1.10 
2 5.29 1.66 0.82 108 92.1 0.41 1.12 
3 5.39 2.02 0.80 111 95.0 0.41 1.39 
4 5.34 1. 76 0.80 111 94.0 0.39 1.22 
5 5.28 2.81 0.80 111 93.1 0.45 2.00 
---------------------------------------------------------------------------------No.8 0 6.99 1.02 1.20 147 111 0.17 0.35 
1 6.88 1.30 1.12 150 111 0.17 0.71 
2 6.50 1.87 1.10 143 104 0.22 1.14 
3 6.47 1.66 1.04 137 103 0.23 0.92 
4 6.20 1.07 1.12 138 104 0.15 0.28 
5 6.33 0.88 1.08 143 107~ 0.09 0.24 
---------------------------------------------------------------------------------No.9 0 5.88 3.26 1.00 145 98.5 0.27 0.98 
1 5.78 4.74 1.10 153 98.0 0.25 1.42 
2 5.71 7.46 1.00 150 97.8 0.23 2.24 
3 5.73 5.76 1.10 148 98.6 0.32 1. 73 
4 5.54 3.56 1.12 146 93.4 0.26 1.07 
5 5.72 1.13 1.08 152 96.9 0.20 0.24 
----------------------------------------------~-.--------------------------------10.10 0 6.63 1.07 0.88 110 117 0.22 0.65 
1 6.52 1. 76 O.U 106 113 0.24 1.27 
2 7.06 2.70 0.86 113 120 0.34 2.01 
3 7.05 2.38 0.84 114 121 0.39 1.81 
4 6.73 1.54 0.88 106 115 0.31 1.02 
5 6.55 1.28 0.84 105 112 0.19 0.79 
---------------------------------------------------------------------------------10.11 0 6.26 1.46 1.12 144 108 0.38 0.89 
1 6.41 1. 84 1.10 150 112 0.40 1.21 
2 6.51 2.78 ' 1.12 152 112 0.45 1.88 
3 6.54 2.66 1.14 141 109 0.55 1.80 
4 6.66 1.84 1.16 152 112 0.49 1.20 
5 6.12 1.81 1.14 155 113 0.43 1.20 
---------------------------------------------------------------------------------10.12 0 4.08 1.33 0.86 112 53.5 0.38 0.75 
1 3.91 1.55 0.84 113 59.0 0.38 0.96 
2 3.90 2.07 0.80 108 58.2 0.46 1.42 
3 3.97 2.44 0.12 110 59.0 0.56 1.68 
4 4.00 2.24 0.14 111 59.1 0.59 1.57 
5 3.86 2.13 0.12 109 58.3 0.59 1.43 
---------------------------------------------------------------------------------
10.13 0 "6.83 1.36 1.00 121 " 120 0.35 0.85 
1 6.28 1.41 1.00 123 119 0.41 0.92 
2 6.26 2.19 0.90 122 116 0.31 1.68 
3 6.60 2.63 0.98 128 123 0.50 ! 1.86 
4 6.23 1.71 0.96 120 117 0.44 1.10 
5 6.16 1.29 1.02 123 116 0.29 0.14 
----------------------------------------------------------------~----------------10.14 0 4.93 0.97 1.04 120 75.5 0.25 0.53 
1 4.12 0.98 1.04 124 74.9 0.29 0.56 
2 4.57 1.07 1.06 115 71.7 0.23 0.63 
3 4.68 1.21 1.06 120 72.5 0.22 0.80 
C 4.48 1.20 1.06 115 71.1 0.24 0.79 
5 4.72 0.94 1.02 121 76.7 0.25 0.52 
-----------------------------------------------------------------~------------~--AbbreviatioDs used: Chol - Cholesterol TG - Tri91Iceride 
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. ' ',,:' 
peak triglyceride level to appear ranged from one hour 
to four hours after · the ingestion of Intralipidl . 
Without Maxolon the mean triglyceride concentration 
rose 57.1 % and peaked at four hours ( Figure 1 ). 
Among the thirteen normal subjects four persons did 
not change the time of peak serum triglyceride level 
to appear, four had their peak serum triglyceride 
levels appear one hour earlier, four had their peak 
serum triglyceride levels appear two hours earlier and 
one had the peak serum triglyceride level appear three 
hours earlier. The mean peak hour with the Maxolon 
injection occurred significantly earlier than the mean 
peak hour without Maxolon injection ( p = 0.0006 ). 
With Maxolon injection, the mean serum triglyceride 
level returned to the mean fasting level at five 
hours. Without Maxolon injection the mean serum 
triglyceride level at six hours was 0.72 mmol/L and 
was significiantly higher than the mean fasting serum 
triglyceride level ( p < 0.01 ) (Figure 1) • . 
Total postprandial triglyceridaemia indicated the 
total mass of triglyceride in the serum for the five, 
six hours following .the ingestion of IntralipidR wi th 



























rlgure 1. Change In serum triglyceride concentration of 
normal sublects after the Ingestion of Intrallpld with and 
without Uaxolon InJection. Results ara expressed as 
mean ± SEM. 0-0 with Maxolon Inlectlon 
• -. without Maxolon InJectton. 
0.00 -I----t---+----I---+----+---+----+---I 
o 1 2 3 5 & 
TIME AFTER THE INGESTION OF INTRALIPID (hours) 
-59-
measured as the area between the serum response curve 
measured hourly (AUe, in units of mmol/L.hr ) and 
baseline ( zero concentration ). The mean Aue without 
Maxolon jnjection was 5.22 mmol/L.hr and was higher 
than the mean Aue of 4. 59 mmol/L. hr with Maxolon 
injection. However, the mean AUe wi thout Maxolon 
injection was 4.33 mmol/L.hr when measured by the area 
under the five hour timet response curve which was not 
significantly different from the mean Aue with Maxolon 
injection ( p = 0.1214 ). A significant correlation 
was found between the fasting serum triglyceride 
concentration and the total postprandial 
triglyceridaemia with Maxolon injection (r = 0.85, 
p < 0.0001 ) and between the fasting serum 
triglyceride concentration and the total postprandial 
triglyceridaemia without Maxolon injection ( r = 0.94; 
p < 0.0001 ). 
The mean TRL triglyceride ( TRL TG )level rose 
after the ingestion of IntralipidR• With Maxolon 
injection the mean TRL TG concentration rose 158 , and 
peaked at two hours. There was a significant 
correlation between the fasting TRL TG concentration 
and the total postprandial TRL triglyceridaemia ( r = 
-60-
0.84, p < 0.001) which is also measured ' as the area 
under the timel response curve ( TRL AUC ). Without 
Maxolon injection the mean TRL TG concentration rose 
130 % and peaked at four hours( figure 2 ), and there 
was also a significant correlation between the 
fasting TRL TG concentration and the total 
postprandial TRL triglyceridaemia ( r = ; 0.94, p < 
0.0001 ). The mean TRL AUC without Maxolon injection 
was 2.88 mmol/L.hr and was higher than the mean TRL 
AUC of 2. 73 mmol/L. hr wi th the Maxolon injection. 
However, the difference was not significant ( p = 
0.2757 ). There was a significant correlation between 
the fasting TRL TG concentration and the TRL AUC with 
and wi thout the Maxolon injection ( r = 0.84, p < 
0.0001 and r = 0.94, p < 0.0001 respectively ). A 
significant correlation was also found between the 
fasting serum triglyceride concentration and the 
fasting TRL TG concentration ( r = 0.95, p < 0.0001 ) 
and between the AUC and the TRL AUC ( r = 0.97, 
p < 0.0001 ). 
Only three out of the nineteen NIDDM patients had 
their serum TG concentration outside the reference 





Figure 2. Change In trIglyceride concentration In TRL 
fraction of normal subJects after the IngestIon of Intrallpld 
with and without Maxolon Inlectlon. Results are expressed 
as maan :I: SEM. 0-0 with Maxolon Inlectlon 
• -. without Maxolon Inlectlon. 
I I I tit I 0.00 -+-----i • ..----+---I~--+-I---+I---I--I--+I---I 
01 23 .. 5 & 
TIME AFTER THE INGESTION OF INTRALIPID (hours) 
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oral lipid loading ( Figure 3 ). The time of peak 
serum triglyceride level to appear ranged from one 
hour to four hours after the lipid loading with a mean 
of three hours. A significant correlation was found 
between the mean fasting serum triglyceride 
concentration and the AUC ( r = 0.94, p < 0.0001 ). 
The mean TRL TG level also rose 162 % after the lipid 
loading ( Figure ' 4 ) and a significant correlation was 
found between the fasting TRL TG concentration and the 
TRL AUC ( r = 0.96, p < 0.0001 ). A significant 
correlation was also observed between the fasting 
serum triglyceride concentration and the fasting TRL 
TG concentration ( r = 0.96, p < 0.0001 ) and between 
the AUC and the TRL AUC ( r= 0.99, p < 0.0001). 
Two of the IGT patients had high fasting serum . 
triglyceride concentrations 3.78 and 3.26 mmol/L. The 
other IGT patients had their fasting serum TG levels 
within the reference range. The mean serum 
triglyceride rose 63.9 % (Figure 3 ) while the mean 
TRL TGrose 108% ( Figure 4 ) after the ingestion of 
the IntralipidR and both peaked at two hours. ' Like the 
other two groups of subjects a significant correlation 




























Figure 3. Change In serum trIglycerIde concentration 
after the Ingestion of Intrallptd. Results are ex~ressed as 
mean :I: SEM for normal sublects, NIDDM and IGT patients 
0-0 normal sublects .-. NIDDM patients 
A-A IGT patients 
0.00 -+-----1---+----+----+---+---+----1 
o 1 2 3 5 
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Figure 4. Change In TRL triglyceride concentration after 
the Ingestton of Intrallpld. Results are expressed as 
maan ± SEM for normal sublects, NIDDM and IGT patients. 
0-0 normal subJects .-. NIDOM patient. 
6-A.IGT patients. 
0.00 .......---.......----1----+----+----+----+-----1 
o t 2 5 
TIME AFTER THE INGESTION OF INTRALIPID (hours) 
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concentration and the AUC (r = 0.97, p < 0.0001) and 
between the mean fasting TRL TG concentration and the 
mean TRL AUC ( r == 0.85, p = 0.0001 ). Unlike the 
other two groups of subjects a significant correlation 
was not observed between the fasting serum TG 
concentration and the fasting TRL TG concentration 
( r = 0.48, p > 0.05 ) and ' between the serum AUC and 
the TRL AUC ( r .= 0.42, p = 0.0810 ). However # when 
the two patients wi th fasting serum concentrations 
greater than 3.00 mmol/L are excluded from the 
calculation a significant correlation was again 
observed between the fasting serum triglyceride 
concentration and the fasting TRL TG concentration 
( r = 0.77, p < 0.005 ) and between the serum AUC and 
the TRL AUC ( r = 0.98, p < 0.0001 ). 
The mean fasting serum TG concentration of NIDDM 
patients and IGT patients were significantly higher 
than the mean fasting serum TG concentration of normal 
subjects ( p < 0.05 and p < 0.0001 respectively). The 
mean fasting serum triglyceride levels of IGT patients 
was sigingicantly higher than the mean fasting serum 
triglyceride level of NIDDM patients (p < 0.05 ) 
( Figure 4 ). With the two IGT patients with fasting 
-66-
serum triglyceride greater than 3.00 mmol/L excluded 
the mean fasting serum triglyceride level became 1.22 
± 0.10 mmol/L and was still higher than the mean 
fasting serum triglyceride level of normal subjects 
( p < 0.0001 ) and the mean fasting serum triglyceride 
of NIDDM patients but the difference was not 
significant ( p = 0.0779 ). The mean fasting TRL TG 
concentration of NIDDM and IGT patients was 
significantly higher than the mean fasting TRL TG 
concentration of normal subjects ( p < 0.05 and p < 
0.0001 respectively). The mean fasting TRL TG 
concentration of IGT patients was higher than the mean 
TRL TG concentration of NIDDM patients but the 
difference was not significant ( p = 0.0783 ). If the 
two IGT patients with" fasting serum triglyceride 
concentrations greater than 3.00 mmol/L are excluded 
from the calculation the mean fasting TRL TG 
concentration of IGT patients was 0.65 ± 0.08 mmol/L 
and was still significantly higher than the mean 
fasting TRL TG' concentration of normal subjects and 
was higher than the mean fasting TRL TG concentration 
of NIDDM patients but the difference was not 
significant ( p = 0.0915 ). The mean serum AUC of 
-67-
NIDDM patients and IGT patients were significantly 
higher than the mean serum AUC of normal subjects 
( p < 0.05 and p < 0.0001 respectively). The mean 
serum AUC of · IGT patients was significantly higher 
than the mean serum AUC of NIDDM patients (p < 
0.05) .If the two IGT patients with fasting serum 
triglyceride concentration greater than 3.00 mmol/L 
are excluded from the calculation the difference 
became not significant ( p = 0.1663 ), but was still 
significantly higher than the mean serum AUC of normal 
subjects ( p= 0.0001 ). The mean TRL AUC of NIDDM 
patients and IGT patients was significantly higher 
than the mean TRL AUC of normal subjects ( p < 0.05 
and p < 0.0001 respectively). The mean TRL AUC of IGT 
patients was higher than the mean TRL AUC of NIDDM 
patients but the difference was not significant ( p = 
0.1904 ). A significant correlation between the 
fasting serum triglyceride concentration and serum AUC 
was observed among the normal subjects, NIDDM patients 
and IGT patien'ts ( r = 0.85, P < 0.0001, r = 0.94, p 
< 0.0001 and r = 0.97, p < 0.0001 respectively. A 
significant correlation was also observed between the 
fasting TRL ' triglyceride concentration and the TRL AUC 
-68-
among the normal subjects, NIDDM patients and IGT 
patients ( r = 0.84, p < 0.0001, r = 0.94, p < 0.0001 
and r = 0.85, p = 0.0001 respectively). There was a 
significant correlation between the serum AUC and the 
TRL AUC among the normal subjects and the NIDDM 
patients ( r = 0.97, p < 0.0001 and r = 0.99, p < 
0.0001 respectively). No correlation was found 
between the serum AUC and the TRL AUC among the IGT 
patients ( r = 0.42, p = 0.137 ). However, if the two 
IGT patients with fasting serum triglyceride 
concentration greater than 3.00 mmol/L are excluded 
from the calculation a significant correlation was 
also observed between the serum AUC and the TRL AUC 
( r = 0.98, p < 0.0001 ). 
Cholesterol 
Mean serum cholesterol concentration of the 
normal subjects, NIDDM patients and IGT patients did 
not change after the ingestion of IntralipidR ( Two -
way analysis of variance: F = 1.62, F = 1~42 and F = 
1. 00 respectively ) ( Figure 5 ). The mean serum 
cholesterol concentration of the NIDDM patients and 
IGT patients was significantly higher than the mean 
-69-
serum cholesterol concentration of normal subjects 
( p < 0.05 and p < 0.0001 respectively). The mean 
' serum cholesterol concentration of IGT patients was 
significantly higher than the mean serum cholesterol 
concentration of NIDDM ' patients (p < 0.001) 
(Figure 5). 
The was a slight increase of the mean TRL 
cholesterol concentration of the normal subjects, 
NIDDM patients and IGT patients after the ingestion of 
IntralipidR wi th the highest values found at three 
hours. The mean TRL cholesterol concentration of all 
the three groups at five hours was not significantly 
different from the mean fasting TRL cholesterol 
concentration ( Figure 6 ). 
HDL-cholesterol 
There was a slight decrease of the mean HDL-
cholesterol concentration of the normal subjects, 
NIDDM patients and IGT patients with the lowest value 
found at three hours. At five hours the mean HDL 
cholesterol concentration of all the three groups was 
not significantly different from the mean fasting HOL 
cholesterol' concentration ( Figure 7 ). The mean HOL 
-70-
F'I~ure 5. Change In serum cholesterol concentration 
af er the Ingestion of Intrallpld. Results are ex~ressed as 
Z mean :t: SEU for normal sublects, NIDDM and IGT patients 
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FIgure 6. Change In TRL cholesterol concentration after 
the Ingestion of Intrallpfd. Results are expressed as 
mean :I: SEM for normal subJects, NIDDM and IGT patients 
0-0 normal subJects .-. NIDDM patients . 
A-A IGT patients. 
O.OO+---+----t----+----+---+---of---oI 
o 1 2 3 4 5 
TIME AFTER THE INGESTION OF INTRALIPID (hours) 
-72~ 
cholesterol concentration of normal subjects was 
higher than the mean fasting HDL concentration of 
NIDDM patients but the difference was not significant 
( p = 0.1157 ). The mean fasting HDL concentration of 
normal subjects was significantly higher than the mean 
fasting HDL concentration of IGT patients (p < 0.01). 
The mean fasting HDL concentration of NIDDM patients 
was higher than the mean fasting HDL concentration of 
IGT patients but the difference was not significant 
( p = 0.0981 ). 
Apo A-I 
The mean Apo A-I concentration of normal 
subjects, NIDDM patients and IGT patients did not 
change after the ingestion of IntralipidR ( two-way 
analysis of variance: F = 0.49, F = 1.45 and F = 1.46 
respectively ) ( Figure 8 ). The mean Apo A-I 
concentration of normal subjects was higher than the 
mean Apo A-I concentration of NIDDM patients and IGT 
patients but the difference was not significant ( p = 
0.1473 and p = 0.0763 respectively). The mean Apo A-I 
concentration of NIDDM patients was higher than the 


































FIgure 7. Change In HDL-cholesterol concentration after 
the Ingestion of Intraltpld. Results are expressed as 
mean ± SEM for normal sublects. NIDD~ and IGT patients. 
0-0 normal subJects .-. NIDDM patients 
A-A IGT patients. 
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FI~ure 8. Change In serum Apo A-I concentration 
af er the Ingestion of Intrallpld. Results are expressed as 
mean :I: SE~ for normal subJects, NIDD~ and IGT patIents 
z 
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difference was not significant ( p = 0.1747 ). 
Apo B 
The mean Apo B concentration of normal subjects, 
NIDDM patients and IGT patients also did not change 
after the ingestion of IntralipidR ( two-way analysis 
of variance: F = 1.14, F = 2.09 and F = 1.46 
respectively ) ( Figure 9 ) . The mean Apo B 
concentration of NIDDM patients and IGT patients was 
significantly higher than the mean Apo B concentration 
of normal subjects ( p < 0.05 and p < 0.0001 
respectively). The mean Apo B concentration of IGT 
patients was significantly higher than the mean Apo 8 



























Figure 9. Change In serum Apo B concentration 
after the Ingestion of Intrallpld. Results are expressed as 
mean % SEU for normal sublects, NIDDM and IGT patients 
0-0 normal sublects .-. NIDDM patIents 
6-61GT patients 
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4.Discussion 
In the present study the possible effect of 
Maxolon in shortening the duration of an oral fat load 
using IntralipidR' was investigated. After establishing 
the effect of Maxolon the changes of postprandial 
. lipoproteins following ingestion of an oral fat load 
of IntralipidR were studied in normal, NIDDM and IGT 
. subjects with Maxolon injection. The variables 
analyzed included serum cholesterol level, serum TG 
level and cholesterol and TG levels in the TRL ( d < 
1.006 ) fraction which consisted of chylomicrons, VLDL 
and their remnants, serum HDL-cholesterol level, serum 
Apo A-I and Apo B levels. The normal subjects included 
in this study were selected to be normolipidemic and 
free of disease. The NIDDM and IGT patients were 
selected to be normolipidemic or only mildly 
hyperlipidemic and free of disease other than 
diabetes. The NIDDM patients were under diet-control 
and received 'no medication. The oral fat tolerance 
tests are most commonly used for the investigation of 
physiological and pathological factors affecting the 
metabolism·of 'exogenous' plasma lipids. The exogenous 
-78·-
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lipide include lipide in chylomicrons entering the 
blood from the thoracic duct during absorption of 
dietary fat or fat in artificial emulsions. Oral fat 
loads of various types have been used. A common 
practice is to administer the fat as a mixed meal. The 
subject is loaded with a roughly estimated amount of 
fat together with carbohydrates and protein in the 
form, for example, of a breakfast of bacon and eggs, 
cream, bread and butter, etc. If only fat is given, it ' 
usually consists of cream or soyabean ' oil [64]. 
Tracers such as labelled fats and vitamin A [65] have 
also been used and the concentration of these tracers 
in blood plasma can be determined by isotopic 
triglyceride analysis, vi tamin A measurements etc. 
IntralipidR used in the present study has the advantage 
. that it is ready to use and its composition is clearly 
indicated. Thus a more accurate amount of fat can be 
given to individuals of different body weight. 
IntralipidR has been suggested as a valid tracer for 
chylomicron metabolism [66] because of its 
. similarities in the kinetics of elimination [67] and 
kinetic behaviour as substrate in vitro for post-
heparin lipase (68). Oral tests suffer from the 
-79-
disadvantage that the time course for the 
disappearance of exogenous plasma triglyceride from 
the blood . stream depends not only on the rate of 
removal of exogenous triglyceride from the blood 
stream, but also on various absorption processes in 
the gastrointestinal tract, the rate of formation and 
of influx into blood of chylomicrons, as well as the 
possible recirculation of removed exogenous 
triglycerides such as VLDL triglyceride. Most of the 
oral tests need to be performed for nine to twelve 
hours. Intravenous fat loading tests have been 
introduced to overcome the influence of the 
gastrointestinal tract. However, these tests suffer 
from the defect that they do not totally resemble the 
physiological condition. Most of the oral tests 
require a duration of nine to twelve hours to complete 
because of the long retention time of the inges-ted 
lipids in the stomach. The retention time is also 
different among individuals. In the present study, 
Maxolon was shown to have the effect of shortening the 
duration of the test significantly to five hours as 
indicated by the earlier appearance of the peak 
triglyceride level and the return of the mean serum 
-80-
triglyceride level at five hours to the mean fasting 
level. When the normal subjects repeated the test 
without Maxolon injection the mean serum triglyceride 
level at six hours was still significantly higher than 
the mean fasting triglyceride level indicating 
incomplete removal of the ingested lipids. The 
shortening of the duration of test time was due to the 
action of Maxolon in decreasing the retention time of 
the administered lipide in the stomach to a minimum. 
The IntralipidR is practically tasteless and easy to 
drink. The amount required could be ingested within 
thirty seconds. No adverse effect was observed except 
one subject suffered from mild diarrhoea. 
The data in the present study are in agreement 
with previous observations [69-71] that show that 
patients with NIDDM and IGT have higher choleserol, 
triglyceride and Apo B levels while HDL-cholesterol 
level and Apo A-I levels are lower than normal non-
diabetic subjects. Atherosclerosis is the most 
frequent complication of diabetes. One of the many 
factors is dyslipoproteinaemia. The most prominent 
feature of dyslipoproteinaemia in diabetes is 
hypertriglyceridaemia [72,73]. Increased triglyceride 
, 
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concentration may be due to diminished . removal of 
triglyceride-rich particles as a result of diminished 
activity of lipoprotein lipase [67] and overproduction 
of VLDL [68]. In the present study the mean serum 
triglyceride concentrations of the NIDDM and IGT 
patients al though wi thin the reference range were 
significantly higher than those of the non-diabetic 
control subjects. The normotriglyceridaemia of the 
NIDDM patients may be due to good blood glucose 
control [74]. It has been suggested that defects in 
the action of insulin on glucose disposal and adipose 
tissue lipolysis may have an important role in the 
development of the higher serum triglyceride levels in 
NIDDM and IGT patients. There may be incomplete 
suppression of lipolysis in both the basal and 
insulin-stimulated states. Thus the supply of the main 
substrate for VLDL TG synthesis may be increased [75]. 
In the present study the fasting TRL triglyceride 
( mainly VLDL ) concentration of NIDDM and IGT 
patients wer~ found to be significantly higher than 
those of the normal subjects. The , impaired 
suppression of adipose tissue lipolysis may have 
important consequences for postprandial metabolism, . 
-82-
since VLDL secretion may continue in these subjects 
due to continued supply of substrate ( which would 
normally be suppressed by the meal-stimulated 
secretion of insulin ). This may exaggerate the 
lipaemia which is normally due to synthesis of 
chylomicrons. In the present study, following the 
ingestion of an amount of IntralipidR proportionate to 
the body weight, all study groups demonstrated a 
significant elevation of their serum TG and TRL TG. 
The TRL TG was not differentiated into chylomicrons, 
VLDL or their remnants. The production rate and 
clearance rate of TG are the same in the steady state, 
if the fractional clearance rate is decreased, there 
will be a new steady state with higher plasma 
concentrations. The clearance of TRL invo! ves 
lipolysis to smaller remnant particles with 
concomitant exchange of lipids and apoproteins with 
HDL [76] and the uptake of the lipolyzed particles by 
the liver receptors .[76,77]. The total postprandial 
serum TO and total postprandial TRL TG of the NIDDM 
and IGT patients were significantly higher than that 
of the normal subjects. There was a significant 
correlation between fasting serum TG concentration and 
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postprandial serum TG and between fasting TRL TG 
concentration and postprandial TRL TG. This was in 
agreement with a previous observation [78]. However 
both the NIDDM and IGT patients showed delayed 
removal of absorbed lipids as compared with the normal 
subjects as demonstrated by the significantly higher 
serum TG levels and higher TRL TG levels than the 
fasting levels at five hours. The good correlation of 
total postprandial triglyceridaemia in the serum and 
TRL fraction indicated that the increase in serum 
triglyceride concentration was due to the increase in 
TRL triglyceride. Subjects with a greater magnitude of 
postprandial triglyceridaemia had a greater amount of 
TRL triglyceride. Triglyceride-rich lipoproteins from 
both the liver and intestine may make a significant 
contribution to postprandial triglyceridaemia [79]. It 
was shown earlier [80] the high incidence of 
atherosclerosis and coronary heart disease in patients 
wi th diabetes might be related to abnormali ties in 
triglyceride-rich lipoprotein metabolism. There may 
be changed composition in the TRL leading to an 
increased elimination from the circulation via 
atherogenic macrophages and smooth muscles cell 
-84-
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pathways [80]. The significantly higher mean fasting 
TRL triglyceride level of the NIDDM and IGT patients 
indicated there might be increased production of VLDL. 
The higher than normal postprandial triglyceridaemia 
of the IGT patients indicated that abnormali ty of 
triglyceride metabolism might precede the 
manifestation of fasting hyperglycaemia, and that the 
IGT patients are also facing an increased risk of 
atherosclerosis (81]. There were two IGT patients with 
mild hypertriglyceridaemia ( 3.78 and 3.26 mmol/L ) 
who showed exaggerated increase in postprandial 
triglyceridaemia. Such an exaggerated increase was not 
shown in the TRL. The reason for this finding is not 
clear. With these two IGT patients excluded, the mean 
fasting serum triglyceride level, mean postprandial 
triglyceride, the mean fasting TRL triglyceride level 
and the mean total postprandial TRL triglyceride of 
the IGT patients were higher than the NIDDM patient 










decreased levels of HDL-cholesterol in NIDDM patients 
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[82,83]. There was a decrease in HOL-cholesterol level 
in all study groups postprandially with a concomitant 
increase in TRL cholesterol concentration. Previous 
studies have shown that there is an exchange of 
cholesterol ester in HOL for triglyceride in TRL 
[84,85]. The triglyceride enrichment of HDL 
postprandial was associated with the lowering of HOL-
cholesterol levels. This postprandial decrease in HDL-
cholesterol might reflect predominantly a reduced 
amount of cholesterol ester associated with each HDL 
particle due to replacement with triglyceride in the 
lipid core, rather than a reduction in the actual 
number of particles [85]. The mean HDL-cholesterol 
levels of the NIDDM and IGT patients were , lower when 
compared with the normal subjects. It has been shown 
that the reduction of the total HOL-cholesterol is due 
mainly to low HDLa cholesterol [86] • The mean 
cholesterol levels of all the study groups did not 
change postprandia11y. The mean serum cholesterol 
levels levels of the NIDDM and IGT patients were 
significantly higher than that of the normal subjects. 
This was in agreement with other studies [87,88]. 
The mean postprandial Apo A-I and Apo 8 levels in 
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all the study groups did not change. These findings 
contrast with those of eohn et a1 [89] but are in 
agreement with those of Hester et a1 [90]. One 
previous report has shown that lipoprotein particles 
increase in size rather than number during the 
postprandial period [91] and therefore a change in 
total apo B concentration might not be expected. 
The mean Apo A-I level in NIDDM and IGT subjects 
was significantly lower than in normal subjects. This 
finding is in accordance with those of Briones et al 
[84]. The mean Apo B level in NIDDM and IGT subjects 
was significantly higher than in normal subjects. This 
finding was in accordance with those of Ikeda et al 
[92]. Apo A-I and apo B levels are respectively 
inversely and directly related to the risk and/or 
severity of coronary disease [93]. 
In conclusion, the present study shows that Maxolon 
may facilitate the operation of an or~l lipid loading 
test using IntralipidR so that the test can be finished 
wi thin a normal working day. The test is able to 
differentiate the differences in postprandial lipid 
metabolism among NIDDM, IGT patients and non-diabetic 
individuals. The results also show that NIDDM and IGT 
-87-
. patients have 
lipoprotein and 
a more atherogenic serum lipid, 
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